BEAM News and Press, Beam Therapeutics Inc. From 12/29/23

2023-12-29 19:03:08 ET More on CRISPR Therapeutics Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed CRISPR Gene Editing: Intellia Vs. Crispr Therapeutics Crispr Therapeutics: The Party Is Over (Rating Downgrade) Cell and gen...

2023-12-27 10:30:00 ET Thematic investing has grown immensely in popularity since 2019. At the heart of this movement is Ark Invest, a family of exchange-traded funds (ETFs) shepherded by renowned investor Cathie Wood. The central theme of Wood's Ark Invest is disruption. Ark's goal is to i...

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company’s board of directors. “Christi...

2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...

2023-11-30 04:36:44 ET Summary Beam Therapeutics focuses on base editing technology, which allows for precise changes at the DNA level and potentially reduces off-target effects. Base editing has the versatility to correct a wide range of point mutations, making it applicable to m...

2023-11-24 12:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-21 15:13:40 ET More on Beam, CRISPR, etc. Intellia: Soon-To-Be Enrollment Completion Brings About Catalysts In 2024 Editas Medicine, Inc. (EDIT) Presents at Stifel 2023 Healthcare Conference (Transcript) Beam Therapeutics: Sale Of Rights To Verve's In Vivo Ca...

2023-11-18 07:15:00 ET When it comes to gene-editing companies on the cutting edge, Beam Therapeutics (NASDAQ: BEAM) is keen to be one of the leaders. While it's a bit of a laggard in terms of its pipeline's maturity compared to a few of its competitors, few would claim that its tec...

2023-11-18 06:49:00 ET Most, if not all, of the market's current mega-cap stocks started out much smaller. Investors who spotted their potential early had opportunities to make fortunes over time. Which smaller stocks today could be monsters in the making? Here's why three Motley Fool c...

2023-11-16 15:54:01 ET More on CRISPR Therapeutics CRISPR Therapeutics: Positive Exa-Cel AdCom Opens Door For Historic Approval Risk And Reward: Evaluating Crispr's Exa-Cel For Sickle Cell Crispr: Upcoming Catalysts, Plenty Of Cash And Strong Partnerships Make It A B...